Esteban Dauden-Tello

Madrid, MD, Spain

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 208 publications

Impact of Psoriasis on Patient Well-Being Across Life Stages: A Cross-Sectional Survey (Inpsight Working Group).

Impact of Psoriasis on Patient Well-Being Across Life Stages: A Cross-Sectional Survey (Inpsight Working Group).

Journal: Psoriasis (Auckland, N.Z.)

Published: March 19, 2026

Treatment-associated phenotype switching between psoriasis and atopic dermatitis.

Treatment-associated phenotype switching between psoriasis and atopic dermatitis.

Journal: Journal of the European Academy of Dermatology and Venereology : JEADV

Published: February 11, 2026

Patient-Reported Well-Being in Value-Based Routine Care in Psoriatic Disease Using Tildrakizumab: 2-Year Data of the Phase IV POSITIVE Study.

Patient-Reported Well-Being in Value-Based Routine Care in Psoriatic Disease Using Tildrakizumab: 2-Year Data of the Phase IV POSITIVE Study.

Journal: Psoriasis (Auckland, N.Z.)

Published: January 05, 2026

Real-World Effectiveness and Safety of Tildrakizumab for Plaque Psoriasis: A 3-Year International Multicenter Retrospective Study.

Real-World Effectiveness and Safety of Tildrakizumab for Plaque Psoriasis: A 3-Year International Multicenter Retrospective Study.

Journal: Dermatology and therapy

Published: November 03, 2025

Differential Expression of Galectin-1 and Galectin-9 in Immune-Mediated Inflammatory Diseases.

Differential Expression of Galectin-1 and Galectin-9 in Immune-Mediated Inflammatory Diseases.

Journal: International journal of molecular sciences

Published: August 11, 2025

Risk of infections in patients with psoriasis treated with biologic agents and new oral small molecules: BIOBADADERM registry.

Risk of infections in patients with psoriasis treated with biologic agents and new oral small molecules: BIOBADADERM registry.

Journal: The Journal of investigative dermatology

Published: June 18, 2025

Real-world drug survival of tildrakizumab for plaque psoriasis: a 3-year international multicentre retrospective study.

Real-world drug survival of tildrakizumab for plaque psoriasis: a 3-year international multicentre retrospective study.

Journal: Clinical and experimental dermatology

Published: May 15, 2025

Antifungal Prophylaxis and Effective Therapy With Bimekizumab in a Patient With Multiresistant Plaque Psoriasis and Recurrent Candidiasis.

Antifungal Prophylaxis and Effective Therapy With Bimekizumab in a Patient With Multiresistant Plaque Psoriasis and Recurrent Candidiasis.

Journal: International journal of dermatology

Published: April 01, 2025

Burden to Partners of People with Psoriasis: Results from the FamilyPso International Study.

Burden to Partners of People with Psoriasis: Results from the FamilyPso International Study.

Journal: American journal of clinical dermatology

Published: March 24, 2025

Patient-Reported Well-Being in Value-Based Routine Care Using Tildrakizumab: 52-week Interim Data of the Phase IV Positive Study.

Patient-Reported Well-Being in Value-Based Routine Care Using Tildrakizumab: 52-week Interim Data of the Phase IV Positive Study.

Journal: Psoriasis (Auckland, N.Z.)

Published: March 06, 2025

Secukinumab for Treatment of Plaque Psoriasis in Real-World Clinical Practice in Spain: A Literature Review.

Secukinumab for Treatment of Plaque Psoriasis in Real-World Clinical Practice in Spain: A Literature Review.

Journal: Journal of clinical medicine

Published: December 16, 2024

Ten-Year Persistence of Biologic Drugs in Psoriasis and Its Relationship with Pharmacogenetic Biomarkers.

Ten-Year Persistence of Biologic Drugs in Psoriasis and Its Relationship with Pharmacogenetic Biomarkers.

Journal: Biomedicines

Published: December 10, 2024

Showing 1-12 of 208

Last Updated: 09/26/2026